Search Videos by Topic or Participant
Browse by Series:

Third-Line Treatment Options for mCRC

Panelists Johanna Bendell, MD, Sarah Cannon; Marwan Fakih, MD, City of Hope; Heinz-Josef Lenz, MD, USC; John L. Marshall, MD, Georgetown; Alan
Published: Monday, Jun 23, 2014
For High-Definition, Click
John Marshall, MD, asks the participants how they would approach third-line treatment in patients with KRAS wild-type metastatic colorectal cancer who have received FOLFOX/bevacizumab as first-line therapy and FOLFIRI/ziv-aflibercept as second-line therapy.

Anti-EGFR therapy in combination with irinotecan is recommended by Marwan Fakih, MD. Heinz-Josef Lenz, MD, would administered chemotherapy based on a number of factors, including the timing since the patient’s last chemotherapy, the presence or absence of symptomatic disease, and tumor burden.

Whether patients should continue bevacizumab as part of third-line therapy remains an open question, Alan Venook, MD, comments. Additionally, dual biologic therapy will be evaluated in future clinical trials, Venook notes.

Wrapping up the discussion, Marshall asks the panelists what dosing schedule they use with cetuximab, and whether they use premedication. Venook, Fakih, Lenz, and Johanna Bendell, MD, administer cetuximab every 2 weeks; Venook, Fakih, and Bendell use premedication at every visit, whereas Lenz uses premedication only once.


Slider Left
Slider Right
For High-Definition, Click
John Marshall, MD, asks the participants how they would approach third-line treatment in patients with KRAS wild-type metastatic colorectal cancer who have received FOLFOX/bevacizumab as first-line therapy and FOLFIRI/ziv-aflibercept as second-line therapy.

Anti-EGFR therapy in combination with irinotecan is recommended by Marwan Fakih, MD. Heinz-Josef Lenz, MD, would administered chemotherapy based on a number of factors, including the timing since the patient’s last chemotherapy, the presence or absence of symptomatic disease, and tumor burden.

Whether patients should continue bevacizumab as part of third-line therapy remains an open question, Alan Venook, MD, comments. Additionally, dual biologic therapy will be evaluated in future clinical trials, Venook notes.

Wrapping up the discussion, Marshall asks the panelists what dosing schedule they use with cetuximab, and whether they use premedication. Venook, Fakih, Lenz, and Johanna Bendell, MD, administer cetuximab every 2 weeks; Venook, Fakih, and Bendell use premedication at every visit, whereas Lenz uses premedication only once.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x